ALRN - Aileron Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
0
0
0
-
0
Cost of Revenue
-
-
-
-
-
Gross Profit
-
-
-
-
-
Operating Expenses
Research Development
16,760
18,448
14,239
10,276
7,832
Selling General and Administrative
12,412
13,454
8,769
7,893
5,059
Total Operating Expenses
29,172
31,902
23,008
18,169
12,891
Operating Income or Loss
-29,172
-31,902
-23,008
-18,169
-12,891
Interest Expense
-
-
-
-
-
Total Other Income/Expenses Net
-
-
-
0
0
Income Before Tax
-28,853
-31,547
-22,604
-18,123
-12,878
Income Tax Expense
-
-
-
-
-
Income from Continuing Operations
-28,853
-31,547
-22,604
-18,123
-12,878
Net Income
-28,853
-31,547
-22,604
-18,123
-12,878
Net Income available to common shareholders
-28,853
-31,547
-22,645
-18,198
-12,949
Reported EPS
Basic
-
-2.14
-3.04
-1.91
-
Diluted
-
-2.14
-3.04
-1.91
-
Weighted average shares outstanding
Basic
-
14,738
7,443
9,499
10,914
Diluted
-
14,738
7,443
9,499
10,914
EBITDA
-
-31,684
-22,879
-17,937
-12,566